MD, MPH, PhD student - Vascular medicine specialist / CCU-AH @HopSaintAntoine / Clinical epidemiology @Sorbonne_Univ_ / EAS Young Fellow @society_eas
Joined June 2017
- Tweets 122
- Following 295
- Followers 147
- Likes 546
6 Photos and videos
Pinned Tweet
29 Aug 2022
I was very happy to present our work during the #ESC2022 : elevated Lp(a) level is associated with Major Adverse Limb Event ! Many thanks to the session moderators #ESCCongress #PAD #lpa @esccardio @TristanMirault @gdetricheMD @GoudotG @jbdefrem @Marcodecarlo72 @MarcBonaca
3
5
20
Alexis F. Guédon retweeted
12 Dec 2024
🦴 Giant cell arteritis & Clonal hematopoiesis (CH) —somatic mutations in HSCs
👥 55.1% of patients with GCA had CH
🔬 TET2 & JAK2 mutations in #GCA ➡️ Relapse & poor outcomes.
👉 Screening for CH may guide tailored therapies.
🔓rmdopen.bmj.com/content/10/4…
@alguedon
3
5
592
Alexis F. Guédon retweeted
19 May 2024
Colchicine is the first anti-inflammatory drug approved for athero-CVD prevention
#CONVINCE tested colchicine in ischemic stroke🧠
The results were presented at #ESOC2024 by Peter Kelly @ESOstroke
ucd.ie/medicine/news/2024/co…
The primary endpoint was negative. A🧵with some thoughts
2
18
45
7,528
Alexis F. Guédon retweeted
4 Jun 2024
🚨Anticoagulation for stroke prevention in AF and Treatment of VTE and Portal Vein Thrombosis in Cirrhosis: Guidance @ISTH
👏Congrats @GattAlexander @VirginiaHdezGea @CukerMd @DebSiegal @SimonStanworth @LaraNRoberts1
🙏Honored to have been a part of this
sciencedirect.com/science/ar…
1
5
25
5,094
Alexis F. Guédon retweeted
30 May 2024
I had such a great time at the #EASCongress! Thanks to the #EASYoungFellows programme I was able to gain so many new experiences and expand my network. Hope to see you all again soon and thanks to everyone who made it such a fabulous congress! #EASCongress2024 #MyEAS2024 #EAS
1
9
39
2,012
1 Jun 2024
I was very happy to present our results from the SPARCL cohort about the association between low ApoE levels and higher incidence of cerebrovascular events at the 2024 @EASCongress ! @society_eas @lasfmv @NSFAthero @GoudotG @gdetricheMD @jbdefrem
5
9
22
1,458
Alexis F. Guédon retweeted
29 May 2024
3 papers in NEJM published simultaneously with presentations by Christie Ballantyne and Bob Rosenson at the European Atherosclerosis Society Congress in Lyon France - documenting huge reductions in remnant cholesterol after siRNA inhibition of ApoC3 and ANGTPL3
2
13
42
2,486
Alexis F. Guédon retweeted
28 May 2024
Also wanted to add, here is the free share link for anyone who needs access:
authors.elsevier.com/a/1j8O4…
24 May 2024
Excited to see our @nih_nhlbi @NIH_NIAMS @MayoCancerCare collaboration looking at #VTE in #VEXAS syndrome out in this issue of @BloodJournal! Over 40% of patients had a VTE. @Yael_Kusne @AtefehGho @bhavishap29 ashpublications.org/blood/ar…
8
29
2,097
31 May 2024
I was very honored to provide my commentary for the @BloodJournal on the very nice paper about thrombosis and VEXAS by the fantastic @emmamgroarke team !
29 May 2024
Check out the commentary on our #VEXAS article in @BloodJournal
1
4
9
1,234
Alexis F. Guédon retweeted
29 May 2024
Check out the commentary on our #VEXAS article in @BloodJournal
27 May 2024
VEXAS syndrome: from a vascular perspective
ow.ly/CzUK50RTI1m #thrombosisandhemostasis
2
7
14
2,867
Alexis F. Guédon retweeted
30 May 2024
1
1
113
Presented at #ERA24:
FLOW trial: In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and death from any cause while slowing loss of kidney function. nej.md/44U3slP
ALT Graphs showing the first major kidney disease event
9
281
679
178,171
Alexis F. Guédon retweeted
14 May 2024
The multi societal #PAD guideline in print at long last… Amazing things can happen when specialties work together, review the evidence, and put the patient at the center. Hats off to a most collaborative writing committee. @herbaronowMD @DartmthSurgHSR @schuyler_jones
14 May 2024
🆕 2024 ACC/AHA/Multisociety Guideline for the Management of Lower
Extremity PAD provides recommendations to guide clinicians in the Tx of patients with lower extremity PAD across its multiple clinical presentation subsets. bit.ly/3K0ypes
#JACC #cvPAD @heatherlgornik
10
22
68
10,863
Alexis F. Guédon retweeted
14 May 2024
1/ Published today: The updated evidence-based recommendations for managing Lower Extremity PAD, originally outlined in the 2016 Guideline, now incorporate the latest research findings to assist clinicians.
✍🏽:@heatherlgornik
📖: @CircAHA
1
39
88
14,174
Alexis F. Guédon retweeted
9 May 2024
3⃣rd edition of the 4EU PharmacoEpi course with #PharmacoEpi students from all over Europe at @UniHeidelberg ! Great discussion on multi-database studies. Stay tuned for next edition in Jan 2025 ! @4EUplusAlliance
sante.sorbonne-universite.fr…
1
3
15
568
Alexis F. Guédon retweeted
22 Apr 2024
📰 Our review is online @ThrombosisRese1 discussing risk factors during the acute phase of DVT that are associated with the development of PTS ⚡️🦵
👏Bravo @lina_2411 !
@PlanquetteSante @DavidMSmadja @GoudotG @SanchezOlivie11 @MedVasc_HEGP
@INNOVTE1
thrombosisresearch.com/artic…
2
2
8
963
Alexis F. Guédon retweeted
25 Mar 2024
The 3rd edition of the 4EU PharmacoEpi course has just started with 22 students from 5 EU universities ! A new extended edition supporting an integrative educational 🇪🇺 program in pharmacoepidemiology in the @4EUplusAlliance
1
2
12
547
Alexis F. Guédon retweeted
5 Mar 2024
👏This state-of-the-art review from #isth2023 summarizes the role of #platelets in ischemic #stroke, as example of thrombo-inflammation, and cerebral venous #thrombosis, which is an immunothrombotic disease.
Fantastic work from @stegnerlab!
rpthjournal.org/article/S247…
23
41
4,576
5 Mar 2024
We are very pleased to share our latest collaboration with @CHUnantes & @MSaintantoine on Takayasu arteritis and the prognostic impact of associated aortitis ! mayoclinicproceedings.org/ar…… #Takayasu @mekinian2 @olivierespitia
1
1
5
219
5 Mar 2024
29